This trial is testing a drug to see if it can treat BOS, a condition that may occur after HCT, a procedure where blood cells are transplanted from one person to another.
- Other Cancers
2 Primary · 6 Secondary · Reporting Duration: 2 Years
Side Effects for
2 Treatment Groups
1 of 2
1 of 2
50 Total Participants · 2 Treatment Groups
Primary Treatment: ruxolitinib · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 75 · All Participants · 17 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the current enrollment for this trial?
"Affirmative. Clinicaltrials.gov hosts data that confirms this clinical trial's ongoing recruitment process, which began on April 19th 2019. Currently the research team is seeking 50 participants from one medical facility for their study and have most recently edited it on September 30th 2021." - Anonymous Online Contributor
Does the study currently cater to individuals over 30 years of age?
"The requirements for participation in this investigation stipulate that the minimum age is 18, while the maximum age to enroll is 75." - Anonymous Online Contributor
Are there any opportunities to participate in this medical experiment presently?
"The trial is open for enrollment, with its initial posting on April 19th 2019 and the most recent edit having occurred on September 30th 2021. This information can be found at clinicaltrials.gov." - Anonymous Online Contributor
Who is eligible to become a participant in this medical experiment?
"This medical trial is admitting 50 bronchiolitis patients aged between 18 and 75. To qualify, applicants must meet the following criteria: Vital Capacity (FVC or SVC); 5th percentile of predicted as lower limit of 90% confidence interval; FEV1/VC < 0.7 or at least the 5th percentile of predicted; Forced Expiratory Volume in 1 second should be less than 75% if with ≥ 10% absolute decline over 2 years; elderly patients need to adhere to NHANESIII calculations for their normal limits; Residual Volume > 120% or RV/Total Lung Capacity outwith 90%. Additionally" - Anonymous Online Contributor
Has the FDA granted approval to ruxolitinib?
"The safety of ruxolitinib is rated a 2 on the 1 to 3 scale, as there has been some evidence collected that suggests it may be safe but no proof yet demonstrating efficacy." - Anonymous Online Contributor
What is the typical application of ruxolitinib?
"Ruxolitinib has been known to be efficacious in treating polycythemia vera, polycythemia and cases where hydroxyurea is either ineffective or intolerable." - Anonymous Online Contributor